Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TPH1 | P17752 | 1/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120726 | 0.99 | PTGER1 (0.42) | PTGER1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL5125554 | 0.97 | NPC1 (0.41) | PTGER1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL5125324 | 0.96 | NPC1 (0.43) | PTGER1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL5117492 | 0.87 | PTGER1 (0.53) | PTGER1SCN8ASCN10AELANEPTGDR2 | |
| SCHEMBL5131361 | 0.86 | PTGER1 (0.52) | PTGER1SCN8ASCN10AELANEPTGDR2 | |
| SCHEMBL4723489 | 0.86 | PTGER1 (0.55) | PTGER1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL5117461 | 0.85 | MAPT (0.45) | PTGER1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL5125663 | 0.84 | PTGER1 (0.50) | PTGER1SCN8ASCN10APTGDR2 | |
| SCHEMBL5115704 | 0.84 | MAPT (0.47) | PTGER1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL5117046 | 0.83 | NPC1 (0.44) | PTGER1NPC1MAPTRAB9AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | PTGER1, PTGER2, PTGER4 | PTGER1 1/4885SMN1; SMN2 2693/4885NPC1 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.